WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016174674) EGR1 TARGETING MOLECULES FOR THE TREATMENT OF INFLAMMATORY AND HYPERPROLIFERATIVE CONDITIONS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/174674    International Application No.:    PCT/IL2016/050439
Publication Date: 03.11.2016 International Filing Date: 26.04.2016
IPC:
A61K 31/122 (2006.01), A61K 31/37 (2006.01), A61K 31/404 (2006.01), A61K 31/473 (2006.01), A61K 31/5415 (2006.01), A61P 29/00 (2006.01), A61P 35/00 (2006.01)
Applicants: THE MEDICAL RESEARCH, INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER [IL/IL]; 6 Weizmann Street 6423906 Tel-Aviv (IL)
Inventors: SARIG, Ofer; (IL).
SPRECHER, Eli; (IL)
Agent: EHRLICH, Gal; G.E. Ehrlich (1995) LTD. 11 Menachem Begin Road 5268104 Ramat Gan (IL)
Priority Data:
62/153,087 27.04.2015 US
Title (EN) EGR1 TARGETING MOLECULES FOR THE TREATMENT OF INFLAMMATORY AND HYPERPROLIFERATIVE CONDITIONS
(FR) MOLÉCULES DE CIBLAGE EGR1 DANS LE TRAITEMENT DE MALADIES INFLAMMATOIRES ET HYPERPROLIFÉRATIVES
Abstract: front page image
(EN)A method of treating an inflammation or a hyperproliferative disease in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of: a compound represented by Formula (I): or a pharmaceutically acceptable salt thereof, a compound represented by Formula (II): and a compound represented by Formula (III): wherein the variables in Formulae (I), (II) and (III) are as defined in the specification.
(FR)La présente invention concerne une méthode de traitement d'une inflammation ou d'une maladie hyperproliférative chez un sujet en ayant besoin. Ladite méthode comprend l'administration au sujet d'une quantité thérapeutiquement efficace d'un composé choisi dans le groupe constitué des éléments suivants : un composé représenté par la formule (I) : ou son sel pharmaceutiquement acceptable; un composé représenté par la formule (II) : et un composé représenté par la formule (III) :, les variables dans les formules (I), (II) et (III) étant telles que définies dans la description.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)